Fig. 5: Progression-free survival stratified by mass spectrometry status as best response. | Blood Cancer Journal

Fig. 5: Progression-free survival stratified by mass spectrometry status as best response.

From: Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Fig. 5

A Progression-free survival stratified by EXENT status as the best response and B progression-free survival stratified by liquid-chromatography mass spectrometry (LC–MS) status as the best response, both using the landmark method from cycle 8 onward.

Back to article page